Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00131066
Status:
COMPLETED
Last Update Posted:
2008-09-22
First Post:
2005-08-15
Brief Title:
Long-Term Follow-Up Study of Psoriasis Patients
Sponsor:
MedImmune LLC
Organization:
MedImmune LLC
Study Overview
Official Title:
Long-Term Safety Follow-Up Study of Psoriasis Patients Who Have Received MEDI-507
Status:
COMPLETED
Status Verified Date:
2008-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the long-term safety and profile of psoriasis patients who have completed participation in a previous study and who received treatment with MEDI-507
Detailed Description:
This study will evaluate the long-term safety and lymphocyte repletion profile of psoriasis patients who have completed participation in a previous study and who received treatment with MEDI-507 Patients must have had an ALC 30 lower than baseline defined as baseline prior to any MEDI-507 exposure or an absolute CD4 count of 250 cellsuL This study will also evaluate the development and durability of anti-MEDI-507 antibodies
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None